1887

Abstract

Since the activity of drugs against grown in microbiological culture can differ from their activity against bacteria present in infected tissues, compounds with optimal activity against phenotypes may be overlooked in drug-discovery programmes that rely on screens. The authors have investigated the use of an cell-culture model to assess the action of drugs on in an environment resembling that encountered during infection. Mycobacterial viability in the model was shown to be regulated by the cell-mediated immune system, with growth inhibited by CD4 T cells at an early stage of infection in BCG-vaccinated mice, and at a later stage after infection in naive mice. Screening of drugs in the model demonstrated a window of pyrazinamide susceptibility that coincides with the onset of the T-cell-mediated immune response in naive or vaccinated mice. It is proposed that pyrazinamide acts on a population of bacteria that are exposed to an acidic environment as a result of immune activation. Clinically, administration of pyrazinamide during the initial phase of treatment reduces the risk of relapse after 6 months, suggesting that the early pyrazinamide-susceptible population may contribute to the later pool of mycobacteria that persist during prolonged chemotherapy.

Loading

Article metrics loading...

/content/journal/micro/10.1099/00221287-148-10-2929
2002-10-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/micro/148/10/1482929a.html?itemId=/content/journal/micro/10.1099/00221287-148-10-2929&mimeType=html&fmt=ahah

References

  1. Barry, C. E.3rd, Slayden, R. A., Sampson, A. E. & Lee, R. E. ( 2000; ). Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59, 221-231.[CrossRef]
    [Google Scholar]
  2. Cole, S. T., Brosch, R., Parkhill, J. & 39 other authors ( 1998; ). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544.[CrossRef]
    [Google Scholar]
  3. Crowle, A. J., Sbarbaro, J. A. & May, M. H. ( 1986; ). Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134, 1052-1055.
    [Google Scholar]
  4. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. ( 1999; ). Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (J Am Med Assoc) 282, 677-686.[CrossRef]
    [Google Scholar]
  5. Espinal, M. A., Laszlo, A., Simonson, L. & 9 other authors ( 2001; ). Global trends in resistance to antituberculosis drugs. World Health Organization–International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344, 1294–1303.[CrossRef]
    [Google Scholar]
  6. Flynn, J. L. & Chan, J. ( 2001; ). Immunology of tuberculosis. Annu Rev Immunol 19, 93-129.[CrossRef]
    [Google Scholar]
  7. Glickman, M. S. & Jacobs, W. R.Jr ( 2001; ). Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 104, 477-485.[CrossRef]
    [Google Scholar]
  8. Global Alliance for TB Drug Development ( 2001; ). Scientific blueprint for tuberculosis drug development. Tuberculosis 81, Suppl 1, 1–52.[CrossRef]
    [Google Scholar]
  9. Heifets, L. & Lindholm-Levy, P. ( 1992; ). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145, 1223-1225.[CrossRef]
    [Google Scholar]
  10. Heifets, L., Higgins, M. & Simon, B. ( 2000; ). Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4, 491-495.
    [Google Scholar]
  11. Klemens, S. P., Sharpe, C. A. & Cynamon, M. H. ( 1996; ). Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother 40, 14-16.
    [Google Scholar]
  12. McKinney, J. D. ( 2000; ). In vivo veritas: the search for TB drug targets goes live. Nat Med 6, 1330-1333.[CrossRef]
    [Google Scholar]
  13. Meighen, E. ( 1991; ). Molecular biology of bacterial luminescence. Microbiol Rev 55, 123-142.
    [Google Scholar]
  14. Mitchison, D. A. ( 1985; ). The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225.[CrossRef]
    [Google Scholar]
  15. Orme, I. M. & Collins, F. M. ( 1994; ). Mouse model of tuberculosis. In Tuberculosis: Pathogenesis, Protection and Control , pp. 113-134. Edited by B. R. Bloom. Washington, DC:American Society for Microbiology.
  16. Russell, D. G. ( 2001; ). Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2, 569-577.[CrossRef]
    [Google Scholar]
  17. Snewin, V. A., Gares, M. P., Gaora, P. O., Hasan, Z., Brown, I. N. & Young, D. B. ( 1999; ). Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67, 4586-4593.
    [Google Scholar]
  18. Wilson, M., DeRisi, J., Kristensen, H. H., Imboden, P., Rane, S., Brown, P. O. & Schoolnik, G. K. ( 1999; ). Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci USA 96, 12833-12838.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/00221287-148-10-2929
Loading
/content/journal/micro/10.1099/00221287-148-10-2929
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error